← Back

Autobio Diagnostics Co Ltd

Autobio Diagnostics Co., Ltd. researches, develops, produces, markets, sells, and services clinical diagnostic products in China and internationally. Its offerings include immunoassay, biochemistry, and microbiology products, along with reagents, instruments, and technical support and training services. The company was formerly known as Lifeclone Diagnostics Co., Ltd. and changed its name to Autobio Diagnostics Co., Ltd. in 2003. Founded in 1998, it is headquartered in Zhengzhou, China, and is a subsidiary of Zhengzhou Autobio Co., Ltd.

Price · split & dividend adjusted
News & notes moving 603658.CG
603658.CG▼

Autobio Diagnostics Reports First-Half 2026 Net Profit of 497 Million Yuan, Down 12.94% Year on Year

Autobio Diagnostics has released its 2026 interim report, showing net profit attributable to the parent company of 497 million yuan, a decrease of 12.94% compared with the same period last year. Total operating revenue was 2.058 billion yuan, a slight decline of 0.12% year on year. Net cash inflow from operating activities was 216 million yuan, down 47.38% year on year. The latest asset-liability ratio was 25.60%, gross margin was 67.25%, and diluted earnings per share was 0.87 yuan.
603658.CG ▼
Jiemian·25dRead more →
603658.CG▼

Autobio Diagnostics first-half net profit attributable to parent was 497 million yuan, down 12.9% year on year

Autobio Diagnostics released its 2026 half-year report. Net profit attributable to the parent in the first half was 497 million yuan, down 12.9% year on year. Operating revenue was 2.06 billion yuan, down 0.1% year on year. Net profit attributable to the parent after deducting non-recurring items was 493 million yuan, down 9.7% year on year. Net operating cash flow was 216 million yuan, down 47.4% year on year. In the second quarter, operating revenue was 1.07 billion yuan, up 0.1% year on year, and net profit attributable to the parent was 261 million yuan, down 13.4% year on year. Research and development expenses in the first half reached 302 million yuan, accounting for 14.68% of operating revenue. The company's products have entered more than 120 countries and regions in overseas markets.
603658.CG ▼
财中社·26dRead more →
603658.CG▲

Autobio Diagnostics' overseas revenue grew 40% year-on-year in the first half

Autobio Diagnostics released its 2026 interim report, with overseas business revenue reaching 220 million yuan, a year-on-year increase of 40.13%. In the first half of the year, the company achieved revenue of 2.058 billion yuan and net profit attributable to the parent of 497 million yuan. Against the backdrop of pressure on the domestic in vitro diagnostics industry from centralized procurement and medical insurance payment reforms, the company has made overseas markets an important strategic direction. As of the first half of the year, Autobio Diagnostics' products have covered more than 120 countries and regions worldwide, obtained 678 EU CE certifications, established a subsidiary in Indonesia, and signed a memorandum of cooperation with a Vietnamese medical group. The company stated that in 2026 it will continue to increase overseas investment and seize opportunities in the global IVD sector.
603658.CG ▲
大河财立方·26dRead more →
603658.CG▲

Antu Bio and Subsidiary Obtain Two Medical Device Registration Certificates

Antu Bio and its wholly-owned subsidiary Antu Instrument recently obtained two medical device registration certificates issued by the Henan Medical Products Administration. The acquisition of these certificates further enriches the company's product menu, meets market demand, and effectively supplements existing testing products, which will gradually enhance the company's overall competitiveness. In the first quarter of 2026, Antu Bio achieved revenue of 992 million yuan and net profit attributable to the parent of 236 million yuan.
603658.CG ▲
财中社·73dRead more →
© 2026 MarketDXAsset